- Global Pharma News & Resources

Glenmark appoints Dipankar Bhattacharjee to its Board of Directors

- Mr. Bhattacharjee was previously President & CEO - Global Generic Medicines of Teva Pharmaceutical Industries Ltd and has over thirty years of global pharmaceutical experience

MUMBAI, India, Aug. 17, 2020 /PRNewswire/ -- Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, announced the appointment of Mr. Dipankar Bhattacharjee as Independent Non-Executive Director on the Board of the organization for a period of five years with effect from 14th August, 2020.

Mr. Bhattacharjee comes with over 30 years of global experience in leading Generics, Specialty and OTC Pharma, Medical Devices, and FMCG businesses. He has led high performing teams to develop and execute business strategies across all stages of business cycles, driving growth and value through commercial innovation and focused R&D investments.

In his previous role, Mr. Bhattacharjee held various senior leadership positions at Teva Pharmaceutical Industries, including President & CEO - Global Generics Medicines, Officer and Member Teva Executive Committee (TEC), and Co-chair in JVs with P&G and Takeda Pharmaceuticals. With strong orientation towards stakeholders including investors, customers and consumers, and deep understanding of payers and regulators, he has consistently delivered short-term and long-term results across multiple geographies and business environments.

Before Teva, Mr. Bhattacharjee worked with leading global organizations such as Bausch & Lomb, Bank of America and Nestle. He holds a Master's degree in Management Studies from Jamnalal Bajaj Institute of Management Studies, University of Mumbai, and a Bachelor's degree in Economics from St. Stephen's College, University of Delhi.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019).

For more information, visit


Glenmark appoints Dipankar Bhattacharjee to its Board of Directors

Editor Details

Last Updated: 17-Aug-2020